An $8bn public-to-private takeout by two private equity firms of the Swedish rare disease specialist collapses because total tenders to the offer fell below a 90% threshold.

Are three FDA clinical holds in less than four days a symptom of lax safety programs at some biotech companies? And what does the latest publication on Aduhelm say about the relationship between safety and accelerated approval?

Plus deals involving Moderna/Metagenomi, Agomab/Origo, Selecta/Ginkgo, Teva/MODAG, Boehringer Ingelheim/Thoeris and X-Chem/ComInnex/Glamorous AI.

I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.